Takeda Pharmaceutical Company Limited — Cyborg Score 7/10
Strong
Pharmaceutical Manufacturing & Biotechnology
Strategic Profile
Takeda maintains its position as a global biopharmaceutical leader through continuous innovation in oncology, gastroenterology, and rare disease therapies. Takeda makes strategic investments in internal and external opportunities to enhance its pipeline, new product launches, and plasma-derived therapies.
Cyborg Score Rationale
In fiscal year 2025, Takeda Pharmaceutical's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. The company has multiple pipeline advances and strategic collaborations, though earnings declined 25.08% year-over-year.
Top Insights
Takeda presented Phase 3 clinical trial results for oveporexton, their first-in-class oral orexin receptor agonist for narcolepsy type 1, with studies meeting all primary and secondary endpoints, with 85% of participants achieving normal sleepiness scores and over 80% reduction in cataplexy rates.
FDA accepted New Drug Application and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 with a PDUFA goal date in the third quarter of this calendar year.
Takeda has partnered with VELA Transport to become the first biopharmaceutical company to transport products between Europe and the U.S. using a revolutionary wind-powered cargo trimaran launching in late 2026, reducing greenhouse gas emissions by up to 99% compared to air freight.
Kim will focus on the CEO transition and serve as interim head of the Global Portfolio Division as Takeda prepares for its next CEO succession in June 2026.
Named Competitors
Regeneron — Rare disease and immunology focus
Vertex — Rare genetic diseases
Novo Nordisk — Gastrointestinal and rare disease therapies
Pfizer — Diversified pharma oncology and specialty care
Recent Developments
(February 2026) FDA grants Priority Review for oveporexton narcolepsy drug
(February 2026) Takeda advances oral Crohn's disease drug TAK-279 with active mid-stage trial
(February 2026) New President appointed to U.S. business with GLP-1 portfolio experience
(2025) Phase 3 clinical trials for oveporexton meet all endpoints with strong efficacy data
Open the full interactive Takeda Pharmaceutical Company Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.